Tadalafil Tablet
Product Images NDC 68071-3781

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3781). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3781 2)

This text appears to be a description of a medication named "Care Pharmaceuticals." It includes information such as the drug's ingredients, dosage (Tadalafil 20mg), lot number, and expiration date. It also mentions the manufacturer's NDC code, serial number, and provides a warning to keep the medication out of reach of children and store it at a controlled temperature of 68-77°F. Additionally, there is a notice to contact a doctor for medical advice on side effects and how to report them to the FDA.*

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

This text provides information related to blood pressure measurements taken in different positions (standing and supine) at specific time intervals. The text includes sections on Diastolic and Systolic blood pressure readings for both positions, along with a note referencing a specific procedure or technique. The data seems to be part of a research study or monitoring process involving the observation of blood pressure variations over time.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

This text provides information about a study on the effects of Tadalafil 20 mg and doxazosin 8 mg on standing systolic blood pressure, represented in millimeters of mercury (mmHg) over a period of time.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

This text appears to be a table displaying different combinations of medications administered at different times (08:00 and 20:00) and their effects on systolic blood pressure (BP). The medications mentioned are 20 mg of tadalafil and 8 mg of doxazosin. The study seems to compare the effects of these medications alone and in combination with each other. The time after administration of tadalafil or placebo seems to be a crucial factor in observing the impact on systolic blood pressure.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

The text provides information related to the IPSS Total Score for Tadalafil tablets 5 mg compared to a placebo over a duration of treatment in weeks. The data suggests a significant change from baseline with a p-value of less than 0.001.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

This text appears to show a comparison between Tadalafil tablets of 5 mg and a placebo over a duration of treatment in weeks. The text also includes a statistical significance marker of *p<0.01.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

Not available.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

This text provides information on a study comparing Tadalafil tablets 5mg to a placebo, showing statistical significance (p<0.01). The duration of treatment is presented in weeks.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.